Abstract:Multidrug resistance (MDR) often leads to the failure of the anticancer treatment. Besides the blockage of those MDR pathways, the development of more potent drugs are of urgent needs but largely postponed due to imbalance between safety and efficacy. The prodrug strategy, especially with bioorthogonal activation has shown immerse potential to balance safety and efficacy, while recent studies focus on few drug entities such as doxorubicin and MMAE, leaving the vast collection of toxins undetermined. Here we have enumerated typical molecular entities ranging from FDA approved drugs (doxorubicin, paclitaxel) to a heated ADC warhead (MMAF-OMe) and a trichothecene toxin (Mytoxin A) to demonstrate that the trans-cyclooctene (TCO) caging may serve as a general prodrug design to increase the therapeutic index for bioactive molecules. These prodrugs can be efficiently activated on-demand by the bioorthogonal activators whose distribution is regulated by the cell specific enzymatic non-covalent synthesis of supramolecular self-assemblies. These cell-specific prodrugs activation could not only reduce the toxicology of drugs but also enhance the synergistic therapeutic effect within a broad range of dose ratio. More importantly, these prodrugs activation share the same activator bearing assemblies, which allows the flexible shift of drug identities to successfully combat MDR cancer in vivo. In general, this versatile bioorthogonal prodrug activation platform is readily applicable to enlarge the therapeutic window for various bioactive molecules. We envision that the spatiotemporal controlled prodrug activation should facilitate the drug discovery and development.

A Dual-Mechanism Targeted Bioorthogonal Prodrug Therapy

Bioorthogonal Chemistry-Based Prodrug Strategies for Enhanced Biosafety in Tumor Treatments: Current Progress and Challenges

Enzymatic Non-Covalent Synthesis of a Versatile Platform for Bioorthogonal Prodrugs Activation to Combat Drug Resistance

A High‐Efficiency Bioorthogonal Tumor‐Membrane Reactor for In Situ Selective and Sustained Prodrug Activation

Engineering Molecular Self-Assembly of Theranostic Nanoprobes for Dual-Modal Imaging-Guided Precise Chemotherapy

Enzymatic non-covalent synthesis of supramolecular assemblies as a general platform for bioorthogonal prodrugs activation to combat drug resistance

Synergistic Enzymatic and Bioorthogonal Reactions for Selective Prodrug Activation in Living Systems

Coordinating Bioorthogonal Reactions with Two Tumor-Microenvironment-responsive Nanovehicles for Spatiotemporally Controlled Prodrug Activation

An All-in-One Bioorthogonal System for Precise Cancer Therapy

Bioorthogonal Prodrug–Antibody Conjugates for On-Target and On-Demand Chemotherapy

Dual stimulus-triggered bioorthogonal nanosystem for spatiotemporally controlled prodrug activation and near-infrared fluorescence imaging

Palladium-Mediated Bioorthogonal System for Prodrug Activation of N -Benzylbenzamide-Containing Tubulin Polymerization Inhibitors for the Treatment of Solid Tumors

Modular Nanoparticulate Prodrug Design Enables Efficient Treatment of Solid Tumors Using Bioorthogonal Activation

Supramolecular Prodrug Nanovectors for Active Tumor Targeting and Combination Immunotherapy of Colorectal Cancer

Acid-Responsive Polymer Micelles for Targeted Delivery and Bioorthogonal Activation of Prodrug through Ru Catalyst in Tumor Cells

Controlled bioorthogonal activation of Bromodomain-containing protein 4 degrader by co-delivery of PROTAC and Pd-catalyst for tumor-specific therapy

Nanovoid-confinement and click-activated nanoreactor for synchronous delivery of prodrug pairs and precise photodynamic therapy

A Synergistic Chemoimmunotherapy System Leveraging PD-L1 Blocking and Bioorthogonal Prodrug Activation

Bioorthogonal chemistry for prodrug activation in vivo

Targeted delivery of PROTAC-based prodrug activated by bond-cleavage bioorthogonal chemistry for microneedle-assisted cancer therapy

Bioorthogonal Janus Microparticles for Photothermal and Chemo‐therapy